Korro Bio (NASDAQ:KRRO) versus Talphera (NASDAQ:TLPH) Head to Head Contrast

Talphera (NASDAQ:TLPH) and Korro Bio (NASDAQ:KRRO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.

Profitability

This table compares Talphera and Korro Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Talphera	N/A	-92.98%	-53.22%
Korro Bio	-1,834.48%	-117.86%	-71.04%

Institutional and Insider Ownership

37.7% of Talphera shares are owned by institutional investors. Comparatively, 13.2% of Korro Bio shares are owned by institutional investors. 3.5% of Talphera shares are owned by insiders. Comparatively, 4.8% of Korro Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Talphera and Korro Bio”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Talphera	$30,000.00	1,781.90	-$14.29 million	($0.31)	-3.32
Korro Bio	$6.39 million	29.74	-$117.26 million	($11.67)	-1.13

Talphera has higher earnings, but lower revenue than Korro Bio. Talphera is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Talphera and Korro Bio, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Talphera	1	1	2	0	2.25
Korro Bio	1	2	6	3	2.92

Talphera presently has a consensus price target of $3.00, indicating a potential upside of 191.26%. Korro Bio has a consensus price target of $16.71, indicating a potential upside of 26.82%. Given Talphera’s higher probable upside, equities analysts plainly believe Talphera is more favorable than Korro Bio.

Volatility & Risk

Talphera has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Comparatively, Korro Bio has a beta of 3, suggesting that its share price is 200% more volatile than the S&P 500.

Summary

Talphera beats Korro Bio on 8 of the 15 factors compared between the two stocks.

About Talphera

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

About Korro Bio

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.